Bacterial immunostat: Mycobacterium tuberculosis lipids and their role in the host immune response

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 50, Issue 1, 2017, Pages 9-18

  Queiroz, Adriano ^a,b   Riley, Lee W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Immune response; Lipids; Mycobacterium tuberculosis

Indexed keywords

CORD FACTOR; CXCL2 CHEMOKINE; DIACYLATED SULPHOGLYCOLIPID; DIACYLTREHALOSE; INTERLEUKIN 12; INTERLEUKIN 6; LIPOARABINOMANNAN; MANNAN; MATRIX METALLOPROTEINASE; MEMBRANE LIPID; METHYLMALONYL COENZYME A; METHYLMALONYL COENZYME A CARBOXYLTRANSFERASE; MYCOLIC ACID; PHTHIOCEROL DIMYCOCEROSATE; POLYACYLTREHALOSE; SCAVENGER RECEPTOR A; SULPHOLIPID I; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CARRIER PROTEIN; LIPID;

ADAPTIVE IMMUNITY; BACTERIAL CLEARANCE; BACTERIAL IMMUNITY; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BONE MARROW DERIVED MACROPHAGE; DNA MICROARRAY; HOMEOSTASIS; HOST RESISTANCE; IMMUNOGENICITY; LIPID COMPOSITION; LIPID METABOLISM; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; CELL WALL; HUMAN; INNATE IMMUNITY; METABOLISM; PHYSIOLOGY;

CELL WALL; HUMANS; IMMUNITY, INNATE; LIPID METABOLISM; LIPIDS; MEMBRANE LIPIDS; MEMBRANE TRANSPORT PROTEINS; MYCOBACTERIUM TUBERCULOSIS;

EID: 85015666725     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/0037-8682-0230-2016     Document Type: Review

References (93)

1. Parrish NM, Dick JD and Bishai WR. Mechanisms of latency in Mycobacterium tuberculosis. Trends Microbiol. 1998;6(3):107-12.
2. Mak A, Thomas A, Del Granado M, Zaleskis R, Mouzafarova N, Menzies D. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med. 2008;178(3):306-12.
3. Bermudez LE, Goodman J. Mycobacterium tuberculosis invades and replicates within type II alveolar cells. Infect Immun. 1996;64 (6):1400-06.
4. Flynn JL, Chan J. Tuberculosis: latency and reactivation. Infect Immun. 2001;69(7):4195-4201.
5. Brennan PJ, Nikaido H. The envelope of mycobacteria. Annu Rev Biochem. 1995;64:29-63.
6. Brennan PJ. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb). 2003;83(1-3):91-7.
7. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998;393(6685):537-44.
8. Munoz-Elias EJ, McKinney JD. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat Med. 2005;11(6):638-44.
9. Jain M, Petzold CJ, Schelle MW, Leavell MD, Mougous JD, Bertozzi CR, et al. Lipidomics reveals control of Mycobacterium tuberculosis virulence lipids via metabolic coupling. Proc Natl Acad Sci USA. 2007;104(12):5133-38.
10. Muñoz-Elias EJ, Upton AM, Cherian J, McKinney JD. Role of the methylcitrate cycle in Mycobacterium tuberculosis metabolism, intracellular growth, and virulence. Mol Microbiol. 2006;60(5): 1109-22.
11. McKinney JD, Höner zu Bentrup K, Muñoz-Elias EJ, Miczak A, Chen B, Chan WT, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature. 2000;406(6797):735-38.
12. Gengenbacher M, Kaufmann SH. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev. 2012;36(3):514-32.
13. Khoo KH, Dell A, Morris HR, Brennan PJ, Chatterjee D. Structural definition of acylated phosphatidylinositol mannosides from Mycobacterium tuberculosis: definition of a common anchor for lipomannan and lipoarabinomannan. Glycobio. 1995;5(1):117-27.
14. Sakamoto K, Kim MJ, Rhoades ER, Allavena RE, Ehrt S, Wainwright HC, et al. Mycobacterial trehalose dimycolate reprograms macrophage global gene expression and activates matrix metalloproteinases. Infect Immun. 2013;81(3):764-76.
15. Middlebrook G, Dubos RJ, Pierce CJ. Virulence and morphological characteristics of mammalian Tubercle bacilli. J Exp Med. 1947;86(2):175-84.
16. Bloch H. Studies on the virulence of tubercle bacilli. Isolation and biological properties of a constituent of virulent organisms. J Exp Med. 1950;91(2):197-218.
17. Noll H, Bloch H, Asselineau J, Lederer E. The chemical structure of the cord factor of Mycobacterium tuberculosis. Biochim Biophys Acta. 1956;20(2):299-309.
18. Bekierkunst A. Acute granulomatous response produced in mice by trehalose-6,6-dimycolate. J Bacteriol. 1968;96(4):958-61.
19. Cantrell SA, Leavell MD, Marjanovic O, Iavarone AT, Leary JA, Riley LW. Free mycolic acid accumulation in the cell wall of the mce1 operon mutant strain of Mycobacterium tuberculosis. J Microbiol. 2013;51(3):619-26.
20. Ojha AK, Baughn AD, Sambandan D, Hsu T, Trivelli X, Guerardel Y, et al. Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant bacteria. Mol Microbiol. 2008(1);69:164-74.
21. Ojha AK, Trivelli X, Guerardel Y, Kremer L, Hatfull GF. Enzymatic hydrolysis of trehalose dimycolate releases free mycolic acids during mycobacterial growth in biofilms. J Biol Chem. 2010;285(23):17380-89.
22. Yang Y, Kulka K, Montelaro RC, Reinhart TA, Sissons J, Aderem A, et al. A hydrolase of trehalose dimycolate induces nutrient influx and stress sensitivity to balance intracellular growth of Mycobacterium tuberculosis. Cell Host Microbe. 2014;15(2):153-63.
23. Ishikawa E, Ishikawa T, Morita YS, Toyonaga K, Yamada H, Takeuchi O, et al. Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J Exp Med. 2009;206 (13):2879-88.
24. Geisel RE, Sakamoto K, Russell DG, Rhoades ER. In vivo activity of released cell wall lipids of Mycobacterium bovis bacillus Calmette-Guérin is due principally to trehalose mycolates. J Immunol. 2005;174(8):5007-15.
25. Bowdish DM, Sakamoto K, Kim MJ, Kroos M, Mukhopadhyay S, Leifer CA, et al. MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose dimycolate and Mycobacterium tuberculosis. PLoS Pathog. 2009;5 (6):e1000474.
26. Quiding-Järbrink M, Smith DA, Bancroft GJ. Production of matrix metalloproteinases in response to mycobacterial infection. Infect Immun. 2001;69(9):5661-70.
27. Takayama K, Wang C, Besra GS. Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis. Clin Microbiol Rev. 2005(1);18:81-101.
28. Barry 3rd CE, Lee RE, Mdluli K, Sampson AE, Schroeder BG, Slayden RA, et al. Mycolic acids: structure, biosynthesis and physiological functions. Prog Lipid Res. 1998;37(2-3):143-79.
29. Korf J, Stoltz A, Verschoor J, De Baetselier P, Grooten J. The Mycobacterium tuberculosis cell wall component mycolic acid elicits pathogen-associated host innate immune responses. Eur J Immunol. 2005;35(3):890-900.
30. Sequeira PC, Senaratne RH, Riley LW. Inhibition of toll-like receptor 2 (TLR-2)-mediated response in human alveolar epithelial cells by mycolic acids and Mycobacterium tuberculosis mce1 operon mutant. Pathog Dis. 2014;70(2):132-40.
31. Layre E, Collmann A, Bastian M, Mariotti S, Czaplicki J, Prandi J, et al. Mycolic acids constitute a scaffold for mycobacterial lipid antigens stimulating CD1-restricted T cells. Chem Biol. 2009;16(1):82-92.
32. Beckman EM, Porcelli SA, Morita CT, Behar SM, Furlong ST, Brenner MB. Recognition of a lipid antigen by CD1-restricted alpha beta+ T cells. Nature. 1994;372(6507):691-94.
33. Glickman MS, Cox JS, Jacobs Jr WR. A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol Cell. 2000;5(4):717-27.
34. Rao V, Fujiwara N, Porcelli SA, Glickman MS. Mycobacterium tuberculosis controls host innate immune activation through cyclopropane modification of a glycolipid effector molecule. J Exp Med. 2005;201(4):535-43.
35. Yuan Y, Zhu Y, Crane DD, Barry 3rd CE. The effect of oxygenated mycolic acid composition on cell wall function and macrophage growth in Mycobacterium tuberculosis. Mol Microbiol. 1998;29(6):1449-58.
36. Dubnau E, Chan J, Raynaud C, Mohan VP, Lanéelle MA, Yu K, et al. Oxygenated mycolic acids are necessary for virulence of Mycobacterium tuberculosis in mice. Mol Microbiol. 2000;36(3): 630-37.
37. Casali N, Riley LW. A phylogenomic analysis of the Actinomycetales mce operons. BMC Genomics. 2007;8:60.
38. Pandey AK, Sassetti CM. Mycobacterial persistence requires the utilization of host cholesterol. Proc Natl Acad Sci USA. 2008;105(11):4376-80.
39. Forrellad MA, McNeil M, Santangelo MP, Blanco FC, García E, Klepp LI, et al. Role of the Mce1 transporter in the lipid homeostasis of Mycobacterium tuberculosis. Tuberculosis (Edinb). 2014;94(2):170-77.
40. Lima P, Sidders B, Morici L, Reader R, Senaratne R, Casali N, et al. Enhanced mortality despite control of lung infection in mice aerogenically infected with a Mycobacterium tuberculosis mce1 operon mutant. Microbes Infect. 2007;9(11):1285-90.
41. Shimono N, Morici L, Casali N, Cantrell S, Sidders B, Ehrt S, et al. Hypervirulent mutant of Mycobacterium tuberculosis resulting from disruption of the mce1 operon. Proc Natl Acad Sci USA. 2003;100(26):15918-23.
42. Uchida Y, Casali N, White A, Morici L, Kendall LV, Riley LW. Accelerated immunopathological response of mice infected with Mycobacterium tuberculosis disrupted in the mce1 operon negative transcriptional regulator. Cell Microbiol. 2007;9(5):1275-83.
43. Queiroz A, Medina-Cleghorn D, Marjanovic O, Nomura DK, Riley LW. Comparative metabolic profiling of mce1 operon mutant vs wild-type Mycobacterium tuberculosis strains. Pathog Dis 2015; 73(8):ftv066. doi: 10.1093/femspd/ftv066.
44. Schlesinger LS, Hull SR, Kaufman TM. Binding of the terminal mannosyl units of lipoarabinomannan from a virulent strain of Mycobacterium tuberculosis to human macrophages. J Immunol. 1994;152(8):4070-79.
45. Strohmeier GR, Fenton MJ. Roles of lipoarabinomannan in the pathogenesis of tuberculosis. Microbes Infect. 1999;1(9):709-17.
46. Mishra AK, Driessen NN, Appelmelk BJ, Besra GS. Lipoarabinomannan and related glycoconjugates: structure, biogenesis and role in Mycobacterium tuberculosis physiology and host-pathogen interaction. FEMS Microbiol Rev. 2011;35(6):1126-57.
47. Nigou J, Gilleron M, Puzo G. Lipoarabinomannans: from structure to biosynthesis. Biochimie. 2003;85(1-2):153-66.
48. Fukuda T, Matsumura T, AtoM, Hamasaki M, Nishiuchi Y, Murakami Y, et al. Critical roles for lipomannan and lipoarabinomannan in cell wall integrity of Mycobacteria and pathogenesis of tuberculosis. MBio. 2013;4(1):e00472-12. doi: 10.1128/mBio.00472-12.
49. Haites RE, Morita YS, McConville MJ, Billman-Jacobe H. Function of phosphatidylinositol in Mycobacteria. J Biol Chem. 2005;280(12):10981-87.
50. Gilleron M, Quesniaux VF, Puzo G. Acylation state of the phosphatidylinositol hexamannosides from Mycobacterium bovis bacillus Calmette Guerin and Mycobacterium tuberculosis H37Rv and its implication in Toll-like receptor response. J Biol Chem. 2003;278(32):29880-89.
51. Jones BW, Means TK, Heldwein KA, Keen MA, Hill PJ, Belisle JT, et al. Different Toll-like receptor agonists induce distinct macrophage responses. J Leukoc Biol. 2001;69(6):1036-44.
52. Dao DN, Kremer L, Guérardel Y, Molano A, Jacobs Jr WR, Porcelli SA, et al. Mycobacterium tuberculosis lipomannan induces apoptosis and interleukin-12 production in macrophages. Infect Immun. 2004;72(4):2067-74.
53. Nigou J, Gilleron M, Rojas M, Garcia LF, Thurnher M, Puzo G. Mycobacterial lipoarabinomannans: modulators of dendritic cell function and the apoptotic response. Microbes Infect. 2002;4(9):945-53.
54. Józefowski S, Sobota A, Kwiatkowska K. How Mycobacterium tuberculosis subverts host immune responses. Bioessays. 2008;30(10):943-54.
55. Quesniaux VJ, Nicolle DM, Torres D, Kremer L, Guerardel Y, Nigou J, et al. Toll-like receptor 2 (TLR2)-dependent-positive and TLR2-independent-negative regulation of proinflammatory cytokines by mycobacterial lipomannans. J Immunol. 2004;172(7):4425-34.
56. Krishnan N, Malaga W, Constant P, Caws M, Chau TTH, Salmons J, et al. Mycobacterium tuberculosis lineage influences innate immune response and virulence and is associated with distinct cell envelope lipid profiles. PLoS One. 2011;6(9):e23870. doi: 10.1371/journal.pone.0023870.
57. Ryll R, Kumazawa Y, Yano I. Immunological properties of trehalose dimycolate (cord factor) and other mycolic acid-containing glycolipids – a review. Microbiol Immunol. 2001;45(12):801-11.
58. Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol. 2009;27(1):393-422.
59. van der Wel N, Hava D, Houben D, Fluitsma D, van Zon M, Pierson J, et al. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell. 2007;129:1287-98.
60. Barral DC, Brenner MB. CD1 antigen presentation: how it works. Nat Rev Immunol. 2007;7:929-41.
61. Karakousis PC, Bishai WR, Dorman SE. Mycobacterium tuberculosis cell envelope lipids and the host immune response. Cell Microbiol. 2004;6(2):105-16.
62. Mendum TA, Wu H, Kierzek AM, Stewart GR. Lipid metabolism and Type VII secretion systems dominate the genome scale virulence profile of Mycobacterium tuberculosis in human dendritic cells. BMC Genomics. 2015;16(1):372.
63. Hatzios SK, Schelle MW, Holsclaw CM, Behrens CR, Botyanszki Z, Lin FL, et al. PapA3 is an acyltransferase required for polyacyltrehalose biosynthesis in Mycobacterium tuberculosis. J Biol Chem. 2009;284(19):12745-51.
64. Dubey VS, Sirakova TD, Kolattukudy PE. Disruption of msl3 abolishes the synthesis of mycolipanoic and mycolipenic acids required for polyacyltrehalose synthesis in Mycobacterium tuberculosis H37Rv and causes cell aggregation. Mol Microbiol. 2002;45(5):1451-59.
65. Sirakova TD, Thirumala AK, Dubey VS, Sprecher H, Kolattukudy PE. The Mycobacterium tuberculosis pks2 gene encodes the synthase for the hepta- and octamethyl-branched fatty acids required for sulfolipid synthesis. J Biol Chem. 2001;276(20):16833-39.
66. Besra GS, Bolton RC, McNeil MR, Ridell M, Simpson KE, Glushka J, et al. Structural elucidation of a novel family of acyltrehaloses from Mycobacterium tuberculosis. Biochemistry. 1992;31(40):9832-37.
67. Saavedra R, Segura E, Leyva R, Esparza LA, López-Marin LM. Mycobacterial di-O-acyl-trehalose inhibits mitogen- and antigen-induced proliferation of murine T cells in vitro. Clin Vaccine Immunol. 2001;8(6):1081-88.
68. Rousseau C, Neyrolles O, Bordat Y, Giroux S, Sirakova TD, Prevost MC, et al. Deficiency in mycolipenate- and mycosanoate-derived acyltrehaloses enhances early interactions of Mycobacterium tuberculosis with host cells. Cell Microbiol. 2003;5(6):405-15.
69. Middlebrook G, Coleman CM, Schaefer WB. Sulfolipid from Virulent Tubercle Bacilli. Proc Natl Acad Sci USA. 1959;45(12): 1801-04.
70. Mougous JD, Petzold CJ, Senaratne RH, Lee DH, Akey DL, Lin FL, et al. Identification, function and structure of the mycobacterial sulfotransferase that initiates sulfolipid-1 biosynthesis. Nat Struct Mol Biol. 2004;11(8):721-29.
71. Kumar P, Schelle MW, Jain M, Lin FL, Petzold CJ, Leavell MD, et al. PapA1 and PapA2 are acyltransferases essential for the biosynthesis of the Mycobacterium tuberculosis virulence factor sulfolipid-1. Proc Natl Acad Sci USA. 2007;104(27):11221-26.
72. Converse SE, Mougous JD, Leavell MD, Leary JA, Bertozzi CR, Cox JS. MmpL8 is required for sulfolipid-1 biosynthesis and Mycobacterium tuberculosis virulence. Proc Natl Acad Sci USA. 2003;100(108):6121-26.
73. Goren MB, D'Arcy Hart P, Young MR, Armstrong JA. Prevention of phagosome-lysosome fusion in cultured macrophages by sulfatides of Mycobacterium tuberculosis. Proc Natl Acad Sci USA. 1976;73(7):2510-14.
74. Gilleron M, Stenger S, Mazorra Z, Wittke F, Mariotti S, Böhmer G, et al. Diacylated sulfoglycolipids are novel mycobacterial antigens stimulating CD1-restricted T cells during infection with Mycobacterium tuberculosis. J Exp Med. 2004;199(5):649-59.
75. Pabst MJ, Gross JM, Brozna JP, Goren MB. Inhibition of macrophage priming by sulfatide from Mycobacterium tuberculosis. J Immunol. 1988;140(2):634-40.
76. Zhang L, English D, Andersen BR. Activation of human neutrophils by Mycobacterium tuberculosis-derived sulfolipid-1. J Immunol. 1991;146(8):2730-36.
77. Rousseau C, Turner OC, Rush E, Bordat Y, Sirakova TD, Kolattukudy PE, et al. Sulfolipid deficiency does not affect the virulence of Mycobacterium tuberculosis H37Rv in mice and guinea pigs. Infect Immun. 2003;71(8):4684-90.
78. Kato M, Goren MB. Synergistic action of cord factor and mycobacterial sulfatides on mitochondria. Infect Immun. 1974;10(4):733-41.
79. Domenech P, Reed MB, Dowd CS, Manca C, Kaplan G, Barry CE 3rd. The role of MmpL8 in sulfatide biogenesis and virulence of Mycobacterium tuberculosis. J Biol Chem. 2004;279(20):21257-65.
80. Cox JS, Chen B, McNeil M, Jacobs Jr WR. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature. 1999;402(6757):79-83.
81. Trivedi OA, Arora P, Vats A, Ansari MZ, Tickoo R, Sridharan V, et al. Dissecting the mechanism and assembly of a complex virulence mycobacterial lipid. Mol Cell. 2005;17(5):631-43.
82. Trivedi OA, Arora P, Sridharan V, Tickoo R, Mohanty D, Gokhale RS. Enzymic activation and transfer of fatty acids as acyl-adenylates in mycobacteria. Nature. 2004;428(6981):441-45.
83. Goren MB, Brokl O, Schaefer WB. Lipids of putative relevance to virulence in Mycobacterium tuberculosis: phthiocerol dimycocerosate and the attenuation indicator lipid. Infect Immun. 1974;9(1):150-58.
84. Liu J, Barry CE 3rd, Besra GS, Nikaido H. Mycolic acid structure determines the fluidity of the mycobacterial cell wall. J Biol Chem. 1996;271(47):29545-51.
85. Camacho LR, Constant P, Raynaud C, Laneelle MA, Triccas JA, Gicquel B, et al. Analysis of the phthiocerol dimycocerosate locus of Mycobacterium tuberculosis. Evidence that this lipid is involved in the cell wall permeability barrier. J Biol Chem. 2001;276(23):19845-54.
86. Rousseau C, Winter N, Pivert E, Bordat Y, Neyrolles O, Avé P, et al. Production of phthiocerol dimycocerosates protects Mycobacterium tuberculosis from the cidal activity of reactive nitrogen intermediates produced by macrophages and modulates the early immune response to infection. Cell Microbiol. 2004;6(3):277-87.
87. Astarie-Dequeker C, Le Guyader L, Malaga W, Seaphanh FK, Chalut C, Lopez A, et al. Phthiocerol dimycocerosates of M. tuberculosis participate in macrophage invasion by inducing changes in the organization of plasma membrane lipids. PLoS Pathog. 2009;5(2):e1000289. doi: 10.1371/journal.ppat.1000289.
88. Pérez E, Samper S, Bordas Y, Guilhot C, Gicquel B, Martín C. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol Microbiol. 2001;41(1):179-87.
89. Gonzalo Asensio J, Maia C, Ferrer NL, Barilone N, Laval F, Soto CY, et al. The virulence-associated two-component PhoP-PhoR system controls the biosynthesis of polyketide-derived lipids in Mycobacterium tuberculosis. J Biol Chem. 2006;281(3):1313-16.
90. Galagan JE, Minch K, Peterson M, Lyubetskaya A, Azizi E, Sweet L, et al. The Mycobacterium tuberculosis regulatory network and hypoxia. Nature. 2013;499(7457):178-83.
91. Singh A, Crossman DK, Mai D, Guidry L, Voskuil MI, Renfrow MB, et al. Mycobacterium tuberculosis WhiB3 maintains redox homeostasis by regulating virulence lipid anabolism to modulate macrophage response. PLoS Pathog. 2009; 5(8):e1000545. doi: 10.1371/journal.ppat.1000545.
92. Cunningham AF, Spreadbury CL. Mycobacterial stationary phase induced by low oxygen tension: cell wall thickening and localization of the 16-kilodalton alpha-crystallin homolog. J Bacteriol. 1998;180(4):801-08.
93. Dunphy KY, Senaratne RH, Masuzawa M, Kendall LV, Riley LW. Attenuation of Mycobacterium tuberculosis functionally disrupted in a fatty acyl-CoA synthetase gene fadD5. J Infect Dis. 2010;201(8):1232-39.